Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ: GLUE ) with a Buy and raises the price target from $30 to $35.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.